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OBJECTIVES: Health care utilization and costs may be elevated
among patients with C-ONLY and IBS+C. Migraine is an appro-
priate comparator because it is chronic, costly, and non-
gastrointestinal. Health care utilization and costs were evaluated
for these three groups. METHODS: A large US health plan
claims database was retrospectively analyzed from January 2003
through December 2005. Three mutually exclusive cohorts were
identiﬁed: 1) C-ONLY: ICD-9 564.0x (N = 91,632); 2) IBS+C:
ICD-9 564.1 and 564.0x (N = 10,952); and 3) Migraine: ICD-
9 346.xx (N = 101,418). Per patient use and costs (charged
amounts) of medical services and prescriptions were assessed
over a period of 3 months prior to and 9 months following ﬁrst
diagnosis. Patients had continuous health plan enrollment during
this period. RESULTS: Total health care charges were $15,808
and $16,378 for patients with C-ONLY and IBS+C compared to
$10,405 among patients with migraine (difference $5403 and
$5,973, both P < 0.0001). Inpatient charges were approximately
2.5 times higher for the C-ONLY cohort and 1.7 times higher
for the IBS+C cohort compared to migraine ($5112 and $3,625,
vs. $2093; both P < 0.0001). Both cohorts had higher charges
for ofﬁce visits compared to migraine ($2460 and $3,050, vs.
$2282; both P < 0.0001). Charges for hospital outpatient ser-
vices were $3913 and $4738 for patients with C-ONLY and
IBS+C, respectively, compared to $2784 for migraine (both P <
0.0001), while charges for other ancillary services were $2578
and $2627 for C-ONLY and IBS+C, respectively, compared to
$1444 for migraine (both P < 0.0001). Prescription drug charges
were slightly lower for C-ONLY, but higher for IBS+C compared
to migraine ($1438 and $2053 vs. $1551; both P < 0.0001).
Charges for ER visits were higher for both cohorts compared to
migraine ($307 vs. $251, P < 0.0001 and $284 vs. $251, P =
0.0059). CONCLUSION: C-ONLY and IBS+C are costly con-
ditions that present greater economic burden to payers compared
to migraine. Institutional costs are primary drivers for constipa-
tion expenditures.
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OBJECTIVES: Because of its long duration, Crohn`s disease
(CD) causes high use of health services and high lifetime costs
for medical care. The aim of the present study was to measure
the annual costs of patients with CD from the Brazilian public
heath perspective and to identify potentially relevant determi-
nants of costs. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their CD patients
during two months. They used a structured questionnaire specif-
ically developed to evaluate resource use by patients with CD.
Costs of medical services (diagnostics and treatment) were con-
sidered as well as costs of medication. Resource use was valued
using government reimbursement for hospital services and gov-
ernment tender prices for drugs. RESULTS: 221 patients were
evaluated. The mean annual cost of one CD patient was R$
2.239,67, including medication, physician, laboratory, diagnos-
tic procedures, hospitalization and surgery costs. Medication,
hospitalization, surgery and laboratory/ diagnostic procedures
accounted, respectively for 79%, 18%, 2% and 1% of the total
annual costs. Mesalazine was the most used drug to initiate CD`s
treatment (59% of the times). Although mesalazine is deemed to
be more expensive than sulfasalazine, there was no statistical dif-
ference between the costs of the patients treated with mesalazine
and sulfasalazine. In fact, due to differences in the mean dosage
of theses drugs, mesalazine daily cost is lower than sulfasalazine.
CONCLUSION: This is the ﬁrst time that CD treatment costs
have been demonstrated from the Brazilian public health per-
spective. Considering that there was no statistical difference in
total costs among patients taking mesalazine and sulfasalazine,
and that medications represent more than 70% of total CD treat-
ment annual costs in the public Brazilian health care system, the
use of mesalazine may represent a reduction factor in the ﬁnan-
cial resource expenditure for the treatment of CD.
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OBJECTIVES: To investigate the potential impact of non-
adherence resulting from multiple daily dosing on cost-utility of
gastrointestinal prophylaxis strategies in preventing NSAID
associated gastrointestinal complications. METHODS: Two
decision analytical models (TreeAge 2005) were developed—one
model incorporating non-adherence resulting from multiple daily
dosing and another model that does not. Each model evaluates
the cost-utility of gastrointestinal prophylaxis in a hypothetical
cohort of patients’ age ≥65 years beginning a 6 month course of
NSAIDs. Patients entering each model were treated with either:
(1.) No Prophylaxis, (2.) Proton Pump Inhibitors (generic
omeprazole od) (3.) misoprostol (200 ug qid), (4.) ranitidine (300
mg bid). Average adherence to therapy: od = 79% ± 14%, bid =
69% ± 15% and qid = 51% ± 20% were obtained from a sys-
tematic review of studies using electronic monitoring devices.
Costs were from the perspective of a 3rd party payer of a Cana-
dian provincial seniors’ drug plan. Cost-Utility was measured 
in terms of cost per quality adjusted life year (QALY) gained, 
relative to no prophylaxis. Probabilistic sensitivity analysis 
using Monte Carlo Simulation was used to generate uncertainty
of results, along with cost-effectiveness acceptability curves.
RESULTS: Misoprostol (200 ug qid) has a greater likelihood
(69.2%) than generic omeprazole (30.8%) of being the optimal
cost-effective strategy at a willingness to pay (WTP) of $50,000
per QALY in the model that does not incorporate non-adherence
resulting from multiple daily dosing. In the model that incorpo-
rates non-adherence resulting from multiple daily dose regimens,
generic omeprazole has a greater likelihood (94.8%) than miso-
prostol (5.2%) of being the optimal cost-effective strategy at a
WTP of $50,000 per QALY. CONCLUSION: Cost-utility results
are sensitive to non-adherence resulting from multiple-daily
dosing. Previous economic models in this area have not incor-
porated this in the analysis. Markov modeling or discrete event
simulation may be better suited to incorporate non-adherence
rates of therapies.
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